Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563431782> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2563431782 endingPage "vii112" @default.
- W2563431782 startingPage "vii112" @default.
- W2563431782 abstract "Background: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive neoplasms arising from virtually any organ. The treatment for small-cell lung carcinoma (SCLC) has been adopted for advanced EP-NECs. This study aimed to review the efficacy and toxicity of amrubicin (AMR) monotherapy, which has shown activity against SCLC as a second-line chemotherapy, for patients with platinum-refractory EP-NECs in single-institution series. Method: We retrospectively reviewed 12 patients who received AMR monotherapy as a second-line or further treatment for platinum-refractory EP-NEC between November 2011 and November 2012 at the department of Medical Oncology, Kanagawa Cancer Center. Results: AMR was administered at 40 mg/mg2 for 3 consecutive days every 3-4 weeks until disease progression. The patients included 9 men and 3 women whose median age was 62.5 years (range, 40-70). The primary site was the esophagus or gastrointestinal tract in 8 patients, the liver or biliary tract in 3 patients, and the prostate in 1 patient. Each patient received a median of 3 treatment cycles (range, 1-15). The overall response rate was 50% (partial response, 33.3%; stable disease, 33.3%). The median progression-free and overall survival periods after AMR monotherapy were 2.5 and 4.8 months, respectively. Grade 3 or 4 adverse events included mainly neutropenia (66.6%) and anemia (50%). Febrile neutropenia developed in 3 patients. No treatment-related death occurred. Conclusion: AMR monotherapy can be considered a useful second-line treatment for platinum-refractory EP-NECs. Further multi-institutional prospective studies are warranted." @default.
- W2563431782 created "2017-01-06" @default.
- W2563431782 creator A5000236073 @default.
- W2563431782 creator A5005587908 @default.
- W2563431782 creator A5013695615 @default.
- W2563431782 creator A5016907235 @default.
- W2563431782 creator A5027783702 @default.
- W2563431782 creator A5058329328 @default.
- W2563431782 creator A5070329351 @default.
- W2563431782 creator A5088961590 @default.
- W2563431782 date "2015-11-01" @default.
- W2563431782 modified "2023-10-16" @default.
- W2563431782 title "Amrubicin therapy for platinum-refractory extrapulmonary neuroendocrine carcinoma: Retrospective single-center analysis" @default.
- W2563431782 doi "https://doi.org/10.1093/annonc/mdv472.28" @default.
- W2563431782 hasPublicationYear "2015" @default.
- W2563431782 type Work @default.
- W2563431782 sameAs 2563431782 @default.
- W2563431782 citedByCount "2" @default.
- W2563431782 countsByYear W25634317822020 @default.
- W2563431782 countsByYear W25634317822023 @default.
- W2563431782 crossrefType "journal-article" @default.
- W2563431782 hasAuthorship W2563431782A5000236073 @default.
- W2563431782 hasAuthorship W2563431782A5005587908 @default.
- W2563431782 hasAuthorship W2563431782A5013695615 @default.
- W2563431782 hasAuthorship W2563431782A5016907235 @default.
- W2563431782 hasAuthorship W2563431782A5027783702 @default.
- W2563431782 hasAuthorship W2563431782A5058329328 @default.
- W2563431782 hasAuthorship W2563431782A5070329351 @default.
- W2563431782 hasAuthorship W2563431782A5088961590 @default.
- W2563431782 hasBestOaLocation W25634317821 @default.
- W2563431782 hasConcept C121332964 @default.
- W2563431782 hasConcept C126322002 @default.
- W2563431782 hasConcept C141071460 @default.
- W2563431782 hasConcept C142424586 @default.
- W2563431782 hasConcept C143998085 @default.
- W2563431782 hasConcept C2776694085 @default.
- W2563431782 hasConcept C2777063308 @default.
- W2563431782 hasConcept C2778850193 @default.
- W2563431782 hasConcept C2780073493 @default.
- W2563431782 hasConcept C71924100 @default.
- W2563431782 hasConcept C87355193 @default.
- W2563431782 hasConcept C90924648 @default.
- W2563431782 hasConceptScore W2563431782C121332964 @default.
- W2563431782 hasConceptScore W2563431782C126322002 @default.
- W2563431782 hasConceptScore W2563431782C141071460 @default.
- W2563431782 hasConceptScore W2563431782C142424586 @default.
- W2563431782 hasConceptScore W2563431782C143998085 @default.
- W2563431782 hasConceptScore W2563431782C2776694085 @default.
- W2563431782 hasConceptScore W2563431782C2777063308 @default.
- W2563431782 hasConceptScore W2563431782C2778850193 @default.
- W2563431782 hasConceptScore W2563431782C2780073493 @default.
- W2563431782 hasConceptScore W2563431782C71924100 @default.
- W2563431782 hasConceptScore W2563431782C87355193 @default.
- W2563431782 hasConceptScore W2563431782C90924648 @default.
- W2563431782 hasLocation W25634317821 @default.
- W2563431782 hasOpenAccess W2563431782 @default.
- W2563431782 hasPrimaryLocation W25634317821 @default.
- W2563431782 hasRelatedWork W1196768483 @default.
- W2563431782 hasRelatedWork W136411592 @default.
- W2563431782 hasRelatedWork W1990697416 @default.
- W2563431782 hasRelatedWork W2053128632 @default.
- W2563431782 hasRelatedWork W2102925359 @default.
- W2563431782 hasRelatedWork W2128269008 @default.
- W2563431782 hasRelatedWork W280698033 @default.
- W2563431782 hasRelatedWork W3037414182 @default.
- W2563431782 hasRelatedWork W4286829519 @default.
- W2563431782 hasRelatedWork W4311331895 @default.
- W2563431782 hasVolume "26" @default.
- W2563431782 isParatext "false" @default.
- W2563431782 isRetracted "false" @default.
- W2563431782 magId "2563431782" @default.
- W2563431782 workType "article" @default.